用STING激动剂进行抗血管治疗的抗瘤效果取决于瘤微环境背景
Justyna Czapla1, Alina Drzyzga1, Sybilla Matuszczak1
1Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
将免疫疗法与抗血管治疗相结合显示出对困难癌症的前景. 仔细的瘤微环境查对于有效的癌症治疗和预测免疫治疗反应至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 向瘤血管是癌症治疗策略,但瘤再生通过替代途径发生.
- 免疫疗法显示出有希望的结果,但面临着抵抗机制.
- 组合疗法旨在在具有挑战性的瘤模型中克服这些局限性.
研究的目的:
- 在黑色素瘤和三阴性乳腺瘤模型中,研究结合免疫疗法 (STING激动剂cGAMP) 与抗血管治疗 (CA4P) 的疗效.
- 评估这种组合疗法是否使瘤对免疫检查点抑制剂 (抗PD-1) 产生敏感性.
主要方法:
- 使用B16-F10黑色素瘤和4T1乳腺瘤小鼠模型.
- 施用了刺痛激动剂cGAMP和血管破坏剂CA4P.
- 分析了瘤生长,瘤微环境 (TME) 使用多重免疫光和流细胞计.
- 对抗PD-1治疗的评估反应.
主要成果:
- 在4T1模型中,组合疗法显著抑制了瘤生长,这与TME极化和NK细胞激活有关,但不是CD8+T细胞.
- 在4T1瘤中,cGAMP的单一治疗不足,这是由于STING蛋白的低含量.
- 在B16-F10瘤中,cGAMP单一治疗通过NK细胞透和CD8+T细胞激活诱导了强烈的抗瘤反应,受益于抗PD-1组合.
- 在4T1模型中,由于缺乏PD-1上调,抗PD-1的治疗效果没有得到改善.
结论:
- 瘤微环境显著影响治疗结果和免疫检查点抑制剂反应.
- 临床前数据强调,在开始抗瘤治疗之前,需要对TME进行评估,以获得最佳结果.
更多相关视频
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
相关概念视频
The Tumor Microenvironment
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
